Abstract
Patients with atrial fibrillation and with documented aortic plaque who were assigned to adjusted-dose warfarin therapy (international normalized ratio 2.0 to 3.0) had an annual rate of cholesterol embolization of 0.7% (95% confidence interval [CI] 0.1% to 5.3%/patient-year). Warfarin-assigned patients with plaque had a lower rate of embolic events (5.9%/year; 95% CI 3.0 to 12) than those on combination low-dose warfarin (international normalized ratio <1.5) plus aspirin (17.3%/year; 95% CI 11 to 27; p = 0.01).
Publication types
-
Clinical Trial
-
Clinical Trial, Phase III
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Anticoagulants / therapeutic use*
-
Aorta, Thoracic / diagnostic imaging
-
Aortic Diseases / complications
-
Aortic Diseases / diagnostic imaging
-
Aortic Diseases / drug therapy*
-
Arteriosclerosis / complications
-
Arteriosclerosis / diagnostic imaging
-
Arteriosclerosis / drug therapy
-
Aspirin / therapeutic use
-
Atrial Fibrillation / complications
-
Atrial Fibrillation / diagnostic imaging
-
Atrial Fibrillation / drug therapy*
-
Drug Therapy, Combination
-
Echocardiography, Transesophageal
-
Female
-
Fibrinolytic Agents / therapeutic use
-
Follow-Up Studies
-
Humans
-
Safety
-
Thromboembolism / complications
-
Thromboembolism / diagnostic imaging
-
Thromboembolism / drug therapy*
-
Treatment Outcome
-
Warfarin / therapeutic use*
Substances
-
Anticoagulants
-
Fibrinolytic Agents
-
Warfarin
-
Aspirin